Company · Private
Rubedo Life Sciences
Uses a chemistry platform to design prodrugs activated inside senescent cells, aiming for tissue-selective clearance.
Listing
Private
Ticker
—
Headquarters
Sunnyvale, US
Founded
2019
Technology
Selective senolytic prodrugs
Category
Longevity thesis
Selectivity, not potency, is the limiting factor for systemic senolytics.
Programmes
- RLS-1496Phase 1
Dermatology and fibrosis
Reference information for research context only. It is not a rating, a valuation or investment advice. Published developments appear in the News archive.